Coverage at a glance
| Indication | Coverage |
|---|---|
| Obesity / chronic weight management (commercial, subject to the benefit exclusion flag) | Varies by plan |
| Commercial drug list changes (California lists narrowing, national lists adding Wegovy tablet) | Varies by plan |
| Weight loss (Anthem Blue Cross Medi-Cal, California Medicaid) | Not covered |
Plan type: Commercial employer and individual plans across the Anthem and Elevance states. Each indication below lists the BMI and clinical thresholds, the prior-authorization documentation, and the published policy it comes from.
This varies by plan. Wegovy and Zepbound both carry the BE code, which Anthem defines as benefit exclusion, meaning the drug may not be covered depending on your plan's design. The PA code alongside it means prior authorization is required on plans where the benefit does exist. Anthem's instruction to members is to log in to the member portal or use the Sydney app to price the medication and check the plan documents. Do that before you assume Tier 2 placement means covered.
One BCBS company, not all. Anthem Blue Cross and Blue Shield is the Elevance Health group of Blue plans, operating in California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia and Wisconsin. Other Blue Cross Blue Shield companies are independent licensees and set their own policies, so nothing on this page applies to Highmark, Premera, BCBS of South Carolina or the other independent Blues. Anthem's own drug lists also differ by state filing, and the California-filed lists have moved away from these drugs faster than the national ones.
Coverage by indication
Anthem's published commercial drug lists place Zepbound and Wegovy at Tier 2 and Saxenda at Tier 3, each annotated PA; BE; QL. The same document defines the codes: "PA = prior authorization. You may need to get benefits approved before certain prescriptions can be filled" and "BE = benefit exclusion. This drug may not be covered depending on your plans design." The same Tier 2 and PA; BE; QL treatment appears on both the California-filed National Drug List Three Tier and the non-California Anthem Blue Cross and Blue Shield Traditional Open Three Tier list, so the benefit-exclusion flag is a group-wide convention rather than a single-state quirk. What Anthem does not publish is the clinical content of the prior authorization: no BMI threshold, comorbidity list, lifestyle-trial duration or continuation rule for these drugs appears in any public Anthem document we could locate.
| Step therapy | Not published. Anthem's commercial drug lists show a PA code on both drugs but no ST code, which indicates prior authorization without a formal step-therapy edit on these list versions. |
What the prior authorization needs:
- Prior authorization is required, per the PA code on Anthem's drug lists
- Your plan design must include the benefit, per the BE benefit-exclusion code on the same lists
- Quantity limit of one pen per week applies to both Wegovy and Zepbound
- Anthem directs members to the member portal or the Sydney app to price the medication and confirm coverage
Source: Anthem Blue Cross National Drug List, Three Tier Drug Plan (DMHC filing, last updated January 1, 2025), anti-obesity GLP-1 and GIP/GLP-1 receptor agonist entries and the drug list code legend. Official payer drug list PDF published through Anthem's Drug List Selection page at anthem.com and hosted on Anthem's formulary vendor (downloaded and read directly). Cross-checked against the Anthem Blue Cross and Blue Shield Traditional Open Three Tier list at student.anthem.com, which shows identical tier and code placement outside California.. Verified August 15, 2026. This row is marked lower confidence: the policy document was confirmed at its public URL but served as an unreadable file, so the policy number and framework were cross-checked against secondary sources.
Anthem's commercial drug list change log records the following. Wegovy: Tier 2 to non-formulary on the California CDI National Drug List, the California DMHC National Drug List, the California CDI Essential Drug List and the California DMHC Essential Drug List, effective July 1, 2025. Zepbound: Tier 2 to Tier 3 on those same four lists, effective July 1, 2025. Zepbound Standard Pen: Tier 3 to non-formulary on the California DMHC National Drug List and the California DMHC Essential Drug List, effective October 1, 2026, with no change on the National Drug List, the National Direct lists, the Traditional Open Drug List or the Essential Drug List. Zepbound KwikPen: added at Tier 2 on those same two California DMHC lists, effective August 1, 2026. Wegovy tablet: non-formulary to Tier 2 on the National Drug List, the National Direct, National Direct Plus and National Direct Preferred lists, the Essential Drug List and the Essential Direct Drug List, and Tier 3 to Tier 2 on the Traditional Open Drug List, effective December 23, 2025, with no change on the four California lists. Saxenda and generic liraglutide have moved repeatedly in both directions across 2025 and 2026.
| Effective date | 2026-10-01 |
Source: Anthem Formulary Update, rolling quarterly commercial drug list changes (Q4 2026 back through 2025), published at anthem.com. Official payer formulary change log PDF (downloaded from anthem.com; the multi-column change table was read by text coordinate so each tier change is mapped to the named drug list rather than inferred from row order). Verified August 15, 2026.
Anthem Blue Cross published a Medi-Cal provider notice dated November 14, 2025 stating that Wegovy, Zepbound and Saxenda would be removed from the Medi-Cal Rx Contract Drugs List effective January 1, 2026 and would no longer be eligible for coverage for weight loss or weight-loss indications. Claims for the three drugs deny with Reject Code 70, product or service not covered, regardless of indication, and previously approved prior authorizations expired. Prior authorization requests are still considered for Wegovy when used for noncirrhotic MASH or cardiovascular disease, and for Zepbound when used for obstructive sleep apnea. Requests for members younger than 21 are reviewed for medical necessity under the federal EPSDT benefit. Ozempic, Rybelsus, Mounjaro, Victoza, Byetta, Bydureon and Trulicity keep a type 2 diabetes diagnosis restriction and deny with Reject Code 80 when it is not met. This applies to California Medi-Cal only.
| Effective date | 2026-01-01 |
Source: Anthem Blue Cross, GLP-1 Coverage Considerations, November 14, 2025 (Medi-Cal Rx), document CA-BC-CD-001363-25-S604. Official payer provider notice PDF (downloaded from providers.anthem.com and read in full). Verified August 15, 2026.
Recent change: Anthem's commercial drug list change log shows the four California-filed lists pulling back from Wegovy and Zepbound since July 2025 while the national lists added Wegovy tablet at Tier 2 in December 2025.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it. Plans that approve reassess at renewal, so know your long-term maintenance dose before you start.
- Start with the Anthem prior-authorization letter template, which cites this plan's policy and the diagnosis codes a reviewer looks for. Pick the indication that matches your clinical picture.
- Read the full coverage picture, denial reasons, and the four appeal pathways at GLP-1 insurance coverage.
- If the prior-authorization request is denied, the appeal letter library has templates by denial reason, covering peer-to-peer review, Level 1 and Level 2 internal appeal, and external review.
- Call the number on your insurance card and ask whether your specific plan includes the weight-management drug benefit before you submit.
- If your plan does not cover the indication you need, compare cash prices in the cost guide or check whether a clinical trial near you fits. Neither one goes through your insurer. Clinical trials cost nothing and many pay you for your time. Some participants get a placebo, decided at random.
Frequently asked questions
Does Anthem cover Wegovy for weight loss?
Wegovy appears on Anthem's commercial drug lists at Tier 2, under the heading anti-obesity GLP-1 receptor agonists, with three codes attached: PA for prior authorization, QL for a quantity limit of one pen per week, and BE for benefit exclusion. Anthem defines BE as meaning the drug may not be covered depending on your plan's design. Wegovy is on the list and prior authorization is required. Whether your employer plan covers the category at all is a separate question, and only your plan documents answer it. Anthem does not publish the clinical criteria it applies to commercial prior-authorization requests for Wegovy, so we cannot cite a BMI threshold from an Anthem source.
Does Anthem cover Zepbound?
Zepbound appears at Tier 2 on Anthem's commercial drug lists under the heading anti-obesity GIP and GLP-1 receptor agonists, with the same three codes as Wegovy: PA, QL at one pen per week, and BE for benefit exclusion. The picture is moving in California. Anthem's change log shows Zepbound going from Tier 2 to Tier 3 on the four California-filed drug lists effective July 1, 2025, then Zepbound Standard Pen moving from Tier 3 to non-formulary on the two California DMHC lists effective October 1, 2026, with Zepbound KwikPen added to those lists at Tier 2 effective August 1, 2026. If you are a California Anthem member on the Standard Pen, that is a change worth calling about before October.
What BMI does Anthem require for GLP-1 coverage?
We cannot answer this from an Anthem source, and we would rather say so than repeat a number we cannot check. Anthem's public Clinical Criteria library covers drugs billed under the medical benefit, meaning injected, infused or implanted products administered in a clinical setting. Wegovy and Zepbound are self-administered pharmacy-benefit drugs, and their commercial prior-authorization criteria are not published on Anthem's public site. Several third-party sites state that Anthem uses BMI 30, or 27 with a comorbidity. That matches what most commercial plans do, but no Anthem-published document confirms it, so we have not put it on this page. Ask your prescriber to pull the current criteria through the Anthem provider portal, or call the pharmacy member services number on your card.
Does Anthem cover GLP-1s for weight loss on Medicaid?
In California, no, as of January 1, 2026. Anthem Blue Cross published a Medi-Cal notice stating that Wegovy, Zepbound and Saxenda were removed from the Medi-Cal Rx Contract Drugs List effective that date and are no longer eligible for coverage for weight loss. Claims deny with Reject Code 70, product or service not covered, regardless of indication, and previously approved prior authorizations expired. Two exceptions survive: prior authorization is still considered for Wegovy when used for noncirrhotic MASH or cardiovascular disease, and for Zepbound when used for obstructive sleep apnea. Members under 21 are reviewed for medical necessity under the federal EPSDT benefit. This is California Medi-Cal only and does not describe Anthem Medicaid plans in other states.
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Each page is built from a published payer policy document, government statute, or independent formulary analysis (KFF). Every indication row carries the source URL and the date we verified it. Where a payer's policy PDF was confirmed at its public URL but served as an unreadable binary, the policy number and coverage framework were cross-checked against secondary sources; those rows are marked lower confidence. Commercial coverage often depends on whether an employer elected the weight-management benefit. Those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
